In one paragraphArticle in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Jiachen LiDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.ORCID https://orcid.org/0009-0002-4073-006X Weiyi XiaDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.
Feng SunDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.
Yingni LiDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.
Yuke HouDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.ORCID https://orcid.org/0000-0003-2887-4116 Huanhuan RenDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.
Xiaolin SunDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.
Yuhui LiDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.ORCID https://orcid.org/0000-0002-5794-8172 Zhanguo LiDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.ORCID https://orcid.org/0000-0002-4422-5485 Tian LiuDepartment of Rheumatology and Immunology, Peking University People's Hospital and Beijing Key Laboratory for Non-invasive Diagnosis and Immunotherapy of Rheumatic Diseases, Beijing, China.ORCID https://orcid.org/0000-0002-1691-8372 Funding
Bethune-Puai Medical Research Fund PAYJ-023
6 · The paper itselfAbstract
objectiveBehçet syndrome (BS) is a systemic autoimmune vasculitis characterized by immune dysregulation involving multiple immune cell subsets. CD161
methodsThis prospective multicenter study included 182 patients diagnosed with BS at the three hospitals between 2018 and 2024, 166 patients with systemic lupus erythematosus (SLE) and 149 patients with rheumatoid arthritis (RA) and 114 patients with healthy controls (HCs). Demographic and clinical data were recorded. CD4
resultsPatients with BS had a significantly higher proportion among total Treg cells and CD4
conclusionPatients with BS exhibit an increased CD161
Identifiers
PMID41846457
PMCPMC13093606
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390